- Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis. [Case Reports]Front Immunol. 2022; 13:995304.FI
- We described a case of IPEX syndrome successfully controlled with dupilumab, an anti-IL4 receptor alpha subunit inhibitor. IPEX syndrome is a rare and generally fatal genetic disorder characterized by immune dysregulation, polyendocrinopathy and enteropathy, mostly diagnosed in early childhood. Nonetheless, cases reported in the last 20 years demonstrated that IPEX clinical spectrum encompasses m…
- PMC Free PDF
- A Case of SAPHO Syndrome Complicated by Uveitis with Good Response to Both TNF Inhibitor and JAKinib. [Case Reports]Case Rep Rheumatol. 2023; 2023:6201887.CR
- CONCLUSIONS: The uniqueness of this case was that the patient had a multiorgan involvement including osteoarticular system, skin, and eye. Both TNFi (adalimumab) and JAKinib (tofacitinib) had a good response to all organs with a net improvement in the quality of life of this patient.
- PMC Free PDF
- Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab). [Journal Article]Int J Pharm. 2023 Jan 26 [Online ahead of print]IJ
- FDA-approved anti-TNFα biopharmaceuticals are successful in treating a range of autoimmune diseases. However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration. In this work, we focus only on structural and functional differences across three…
- Publisher Full Text (DOI)
- Perforation in interstitial keratitis associated with hidradenitis suppurativa: medical and surgical management. [Journal Article]BMJ Case Rep. 2023 Jan 27; 16(1)BC
- We present a case of bilateral interstitial keratitis leading to perforation in a woman with hidradenitis suppurativa (HS). A woman in her mid-20s with a history of HS and Grave's disease was referred to the corneal service with loss of vision and pain in both eyes since childhood. She was found to have circumferential thinning and steepening affecting her peripheral cornea bilaterally. Corrected…
- Publisher Full Text (DOI)
- Juvenile idiopathic arthritis in an adult Filipino female: A case report. [Journal Article]Int J Rheum Dis. 2023 Jan 27 [Online ahead of print]IJ
- CONCLUSIONS: JIA is a complicated disease which begins early in life and affects patients even in adulthood. These patients may suffer from arthritis with permanent joint deformities and uveitis, among other disabilities that make daily tasks impossible, impacting patients both mentally and socially.
- Publisher Full Text (DOI)
- Clinicopathologic spectrum of renal lesions following anti-TNF-alpha inhibitor therapy: A single center experience. [Journal Article]Kidney360. 2023 Jan 27 [Online ahead of print]K
- CONCLUSIONS: The renal lesions during anti-TNF-alpha therapy have an autoimmune basis such as ANCA, lupus or lupus-like disease, correlated with new onset serology, while others were similar to those observed in the control group. Renal biopsy findings integrated with clinical features and therapy can identify the underlying pathophysiologic process for appropriate management.
- Publisher Full Text (DOI)
- Use of Novel Biological Agent in Severe Ulcerative Colitis with Poor Response to Initial Therapy: A Case Report. [Journal Article]
- Ulcerative colitis is a condition of chronic inflammation affecting the large intestine. The disease is typically characterized by periods of active inflammation alternating with periods of remission. For patients with moderate to severe ulcerative colitis, the first line for induction therapy options includes biologic agents (with or without an immunomodulator) or glucocorticoids. This case high…
- PMC Free PDF
- Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019. [Journal Article]J Med Virol. 2023 Jan 26 [Online ahead of print]JM
- CONCLUSIONS: Based on the FAERS database, we profiled delayed cutaneous hypersensitivity reactions related to infliximab or adalimumab application in patients with COVID-19 with more points of occurrences, clinical characteristics, and prognosis. This article is protected by copyright. All rights reserved.
- Publisher Full Text (DOI)
- Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. [Review]Clin Cosmet Investig Dermatol. 2023; 16:135-148.CC
- To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became apparent that the efficacy of adalimumab in daily practice was highly variable. In our review, we highlighted the current evidence from literature on the use of biologics in HS in a real-life setting, particularly adalimu…
- PMC Free PDF
- Epidemiology, Treatment, and Outcomes of Juvenile Idiopathic Arthritis-Associated Uveitis: A Multi-Institutional Study in Taiwan. [Journal Article]Ocul Immunol Inflamm. 2023 Jan 25 [Online ahead of print]OI
- CONCLUSIONS: Late age at JIA-U diagnosis and male predominance were distinctive in Taiwan. For patients with inactivity lasting ≥ 6 months was achieved, they still required close follow-up due to the high reactivation rate within 2 years. Female had poorer ocular outcomes.
- Publisher Full Text (DOI)
- Health-related quality of life improvement by adalimumab therapy in patients with rheumatoid arthritis in Taiwan: A nationwide prospective study. [Journal Article]J Chin Med Assoc. 2023 Jan 24 [Online ahead of print]JC
- CONCLUSIONS: HRQoL improved after initiation of adalimumab therapy in Taiwanese patients with moderate-to-severe RA.
- Publisher Full Text (DOI)
- DRESS/DiHS syndrome induced by Propylthiouracil: a case report. [Case Reports]
- CONCLUSIONS: Propylthiouracil is a rare cause of the DRESS/DiHS syndrome, which typically consists of severe dermatitis and various degrees of internal organ involvement. We want to emphasize through this severe case that DRESS/DiHS syndrome should be promptly recognized to hasten recovery.
- PMC Free PDF
- Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. [Randomized Controlled Trial]Br J Dermatol. 2023 Jan 23; 188(1):22-31.BJ
- CONCLUSIONS: Clinical responses observed through week 16 of BE SURE in patients randomized to bimekizumab were sustained through 104 weeks of treatment, regardless of Q4W or Q8W maintenance dosing. Response rates were also sustained through week 104 in patients who switched from adalimumab to bimekizumab at week 24, and were similar to those observed in the bimekizumab groups. Bimekizumab was well tolerated with no new safety signals.
- Publisher Full Text (DOI)
- B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab. [Journal Article]Br J Dermatol. 2023 Jan 23; 188(1):52-63.BJ
- CONCLUSIONS: This highlights the potential for targeting B-cell and complement pathways in HS treatment and the potential of stratifying patients at baseline to the most suitable treatment based on the skin transcriptome. CCL28 has not previously been identified in HS skin and has potential clinical relevance due to its antimicrobial function and homing of B and T cells at epithelial surfaces. Our results provide data to inform future translational and clinical studies on therapeutics in HS.
- Publisher Full Text (DOI)
- Evaluation of adalimumab effects on left ventricle performance by echocardiography indexes among patients with immunosuppressant refractory ulcerative colitis. [Journal Article]
- CONCLUSIONS: The present perusal found no deterioration in left ventricular function indexes with ADA intervention among patients with IBD without cardiac ailment. Thus, prescribing the anti-TNF to alleviate the inflammation can be carried out with less concern about cardiac consequences and considering other adverse traces in the target group.
- PMC Free PDF
- First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. [Journal Article]Expert Opin Drug Saf. 2023 Jan 23 [Online ahead of print]EO
- CONCLUSIONS: Despite seemingly different nature and frequencies, ADRs are the second reason of treatment discontinuation for both bDMARDs. Furthermore, 2-, 5- and 10-year drug survival is longer for ETN compared to ADA.
- Publisher Full Text (DOI)
- Update on the systemic management of non-infectious uveitis in children and adolescents. [Review]Surv Ophthalmol. 2023 Jan 19 [Online ahead of print]SO
- Non-infectious uveitis (NIU) in children and adolescents is a rare but treatable cause of visual impairment in children. Treatments for pediatric NIU and their side effects, alongside the risks of vision loss and need for long-term disease monitoring, pose significant challenges for young patients and their families. Treatment includes local and systemic approaches and this review will focus on s…
- Publisher Full Text (DOI)
- Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019. [Journal Article]Hepatol Res. 2023 Jan 20 [Online ahead of print]HR
- CONCLUSIONS: Although liver-related adverse events are largely caused by host immunity and other constitutional factors, differences in primary diseases, countries, and historical backgrounds lead to differences in the number of reports. Securing an appropriate database and a mechanism to collect real-time information on the frequency of adverse drug reactions is warranted. This article is protected by copyright. All rights reserved.
- Publisher Full Text (DOI)
- Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies. [Journal Article]Br J Dermatol. 2022 Nov 17 [Online ahead of print]BJ
- CONCLUSIONS: This study demonstrates that keratinocytes actively recruit immune cells to HS epidermis and interactions between these cells drive a broad inflammatory profile in HS epidermis. Targeting epidermal inflammation in HS with novel topical formulations may be highly efficacious with reduced systemic side-effects.
- Publisher Full Text (DOI)
- Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort. [Multicenter Study]
- The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment in inflammatory bowel disease (IBD). The aim was to analyze the association between these variants and the long-term response to anti-TNF drugs in pediatric IBD. We performed an observational, multicenter, ambispective study in which we selected 340 IBD patients under 18 yea…
- PMC Free PDF
- Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study. [Journal Article]
- CONCLUSIONS: Our clinical experience suggests that dual therapy may be an option for pediatric patients with moderate and severe courses of IBD with limited therapeutic options.
- PMC Free PDF
- Dupilumab-Induced Lichen Planus: A Case with Oral and Cutaneous Eruptions. [Case Reports]
- Lichen planus is a chronic, inflammatory, immune-mediated dermatosis affecting the patient's skin, scalp, mucous membranes, and nails. Drug-induced lichen planus is described after the administration of antimalarials, β-blockers, methyldopa, NSAIDs, penicillamines, and sodium aurothiomalate. The use of biologicals such as adalimumab, etanercept, and infliximab has also been linked with the appear…
- PMC Free PDF
- Lessons Learned From a Case of Behcet's Disease Presenting With Fever and Life-Threatening Venous Thromboembolism. [Case Reports]
- Infection mimics pose a challenge in the world of infectious diseases. Fever of unknown origin (FUO) requires careful consideration for a broad range of diagnoses. The answer often lies in a careful history and dedicated clinical examination. A delay in diagnosis can result in greater morbidity for the patient. We present the diagnostic challenges in a patient with an infection mimic, Behcet's di…
- PMC Free PDF
- Vaccines in children exposed to biological agents in utero and/or during breastfeeding: are they effective and safe? [Journal Article]J Crohns Colitis. 2023 Jan 18 [Online ahead of print]JC
- CONCLUSIONS: Vaccines seems to be effective in infants exposed to biologics in utero. Inactivated vaccines are probably safe, whereas live-attenuated vaccines should be avoided while the children have detectable levels of biological drugs. Vaccines (non-live and live) are probably safe in children breastfed by mothers treated with biologics.
- Publisher Full Text (DOI)
- Adalimumab-induced sensory vasculitic neuropathy. [Journal Article]Drug Ther Bull. 2023 Jan 17 [Online ahead of print]DT
- Publisher Full Text (DOI)
- Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission. [Journal Article]Dig Dis Sci. 2023 Jan 16 [Online ahead of print]DD
- CONCLUSIONS: In this post hoc analysis, a similar magnitude in the absolute difference of efficacy at week 6 among biologic-naïve patients was observed using indirect comparisons of phase 3 clinical trial data as was observed in VARSITY. Indirect comparisons using patient-level clinical trial data could be used to inform drug choices for future head-to-head trials and guide positioning of drugs in the absence of head-to-head trials.
- Publisher Full Text (DOI)
- Adalimumab combined with erythropoietin improves recovery from spinal cord injury by suppressing microglial M1 polarization-mediated neural inflammation and apoptosis. [Journal Article]Inflammopharmacology. 2023 Jan 15 [Online ahead of print]I
- CONCLUSIONS: ADM combined with EPO improves recovery from SCI by suppressing microglial M1 polarization-mediated neural inflammation and apoptosis.
- Publisher Full Text (DOI)
- Impact of stress on the immunogenic potential of adalimumab. [Journal Article]J Pharm Sci. 2023 Jan 12 [Online ahead of print]JP
- Monoclonal antibodies against tumor necrosis factor-alpha (TNFα) are widely used for treatment of inflammatory diseases. However, despite the inhibitory effect this class of drugs has on the immune system, anti-drug antibodies are often formed with continuous use. Particles formed during stress conditions, which can be used to simulate storage and handling conditions of commercial antibodies, hav…
- Publisher Full Text (DOI)
- Drugs and Lactation Database (LactMed): Adalimumab [BOOK]Drugs and Lactation Database (LactMed). National Library of Medicine (US): Bethesda (MD)BOOK
- Limited information indicates that maternal adalimumab injections produce low levels in breastmilk and do not adversely affect the nursing infant. Because adalimumab is a large protein molecule with a molecular weight of about 148,000 Da, it is likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Most experts and professional gu…
- Treatments for early-stage Dupuytren's disease: an evidence-based approach. [Review]J Hand Surg Eur Vol. 2023 Jan 13 [Online ahead of print]JH
- Current treatments for Dupuytren's disease are limited to late-stage disease when patients have developed flexion contractures and have impaired hand function. They all have limitations, including the risk of recurrence and complications. The use of treatments for early-stage disease, such as intralesional steroid injections or radiotherapy which lack a clear biological basis or evidence of effec…
- Publisher Full Text (DOI)